Listen on the go
CORRECT!
Next question
touchIMMUNOLOGY touchIMMUNOLOGY

Start Learning

Touch Loading image
CONFERENCE HUB
Start Learning
Bimekizumab on structural damage in r-axial SpA & remote monitoring vs face-to-face
Immunometabolism in MASH therapies: a new frontier in treating liver inflammation
JOURNALS
Start Learning
Immunometabolism in MASH therapies: a new frontier in treating liver inflammation
3d medical x ray of knee pain with arthritis inflammation and tendon injury, copy space
JOURNALS
Start Learning
Clinical Approach to the Care of Patients with Immune Checkpoint Inhibitor-associated Inflammatory Arthritis
JOURNALS
Start Learning
Coming soon! touchIMMUNOLOGY Future Leaders 2025
Bioinformatics immuno-oncology
JOURNALS
Start Learning
Shaping Immuno-oncology and Precision Medicine through Bioinformatics: Celebrating a pioneer in progress, Hassan Abushukair
infliximab ulcerative colitis
JOURNALS
Start Learning
Increased infliximab clearance in patients hospitalized with severe ulcerative colitis may lead to underexposure
JOURNALS
Start Learning
Advancing Rheumatology Through Innovation, Education and Patient-Centred Care: An Interview with Future Leader Dr Sham Santhanam
JOURNALS
Start Learning
Highlights from EULAR 2024: Advancing rheumatology
Bimekizumab Shows Comparable One-Year Efficacy in Male and Female axSpA Patients in Phase 3 BE MOBILE Trials
JOURNALS
Start Learning
Bimekizumab Shows Comparable One-Year Efficacy in Male and Female axSpA Patients in Phase III BE MOBILE Trials
Epinephrine 1mg Nasal Spray Gains Approval for Type I Allergic Reactions in Children
JOURNALS
Start Learning
Epinephrine 1mg Nasal Spray Gains Approval for Type I Allergic Reactions in Children Over 4 Years, who Weigh 15 to <30 kg

to view Favourites, Keep Notes and Track CME Credits

Favourites
Bridging Research and Clinical Practice in Hepatology: EASL’s Approach to Liver Disease in Europe
View
Screening for Interstitial Lung Disease in Systemic Autoimmune Rheumatic Diseases: Muhammad Nisar, BSR 2025
View
RMDs: What to Expect in 2025
View
Mirikizumab maintains efficacy in patients with Crohn’s disease previously treated with ustekinumab: One-year results from VIVID-2
View
Multidisciplinary insights: Navigating the challenges of systemic mastocytosis diagnosis and management
View
Advancing the Role of Bone Turnover Markers in Osteoporosis Management: Stuart Silverman, WCO-IOF-ESCEO 2025
View
Findings from the Spring Study – CM-101 for Primary Sclerosing Cholangitis: Paul Pockros, DDW 2025
View
Advancing Osteoarthritis Research Through Immunology and Clinical Insight: An Interview with Future Leader, Dr Tom Appleton
View
Coming soon! touchIMMUNOLOGY Future Leaders 2025
View
Honouring Prof. Marcus Maurer
View
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
Close Popup